219 related articles for article (PubMed ID: 1978251)
1. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
2. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
Wolf CR
IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
4. Dinucleotide repeat polymorphism at the human debrisoquine 4-hydroxylase (CYP2D) locus.
Polymeropoulos MH; Rath DS; Xiao H; Merril CR
Nucleic Acids Res; 1991 Apr; 19(8):1961. PubMed ID: 2030982
[No Abstract] [Full Text] [Related]
5. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
Nebert DW
Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
[No Abstract] [Full Text] [Related]
6. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
7. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
[TBL] [Abstract][Full Text] [Related]
9. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Caporaso N
Ann Ist Super Sanita; 1991; 27(4):621-30. PubMed ID: 1820735
[TBL] [Abstract][Full Text] [Related]
10. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
Vineis P; Landi MT; Caporaso N
Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
12. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
13. NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.
Mura C; Broyart JP; Jacqz E; Elion J; Krishnamoorthy R
Nucleic Acids Res; 1991 Mar; 19(5):1162. PubMed ID: 1673559
[No Abstract] [Full Text] [Related]
14. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
16. [Study of transcription of the human cytochrome P450IID6 gene by polymerase chain reaction].
Krynetskiĭ EIu; Kovaleva IE
Mol Biol (Mosk); 1992; 26(4):943-8. PubMed ID: 1435785
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
18. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
19. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
Evans WE; Relling MV
Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
